The Cigna Group

Ladies and gentlemen, thank you for standing by for Cigna's first quarter 2021 results review. At this time, all callers are in a listen-only mode. We will conduct a question and answer session later during the conference and review procedures on how to interview to ask questions at that time. If you should require assistance during the call, please press star zero on your touchtone phone. As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded. We'll begin by turning the conference over to Ms. Alexis Jones. Please go ahead, Ms. Jones.

Good morning, everyone, and thank you for joining today's call. I am Alexis Jones, Lead Principal for Investor Relations. With me on the line this morning are David Cordani, our President and Chief Executive Officer, and Brian Ivenko, Cigna's Chief Financial Officer. In our remarks today, David and Brian will cover a number of topics, including Cigna's first quarter 2021 financial results, as well as an update on our financial outlook for 2021. As noted in our earnings release, when describing our financial results, Cigna uses certain financial measures, adjusted income from operations, and adjusted revenues, which are not determined in accordance with accounting principles generally accepted in the United States, otherwise known as GAAP. A reconciliation of these measures to the most directly comparable GAAP measures, shareholders' net income and total revenues respectively, is contained in today's earnings release, which is posted in the Investor Relations section of Cigna.com. We use the term labeled adjusted income from operations and adjusted earnings per share on the same basis as our principal measures of financial performance. In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2021 and future performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the FEC. Before turning the call over to David, I will cover a few items pertaining to our financial results and disclosures. Regarding our results, in the first quarter, we recorded an after-tax special item charge of $101 million, or 29 cents per share, related to debt extinguishment costs incurred during the period, as well as an after-tax special item charge of $22 million, or 6 cents per share, for integration and transaction-related costs. We also recorded an after-tax special item benefit of $21 million, or 6 cents per share, related to charges associated with litigation matters. As described in today's earnings release, special items are excluded from adjusted income from operations and adjusted revenues in our discussion of financial results. As previously noted, as a result of the sale of the group Disability and Life Business, In our first quarter earnings release and quarterly financial supplement, Corporate and Other Operations combines the results previously reported as Corporate and the segment previously reported as Group Disability and Other. In our security filings, the segment previously reported as Group Disability and Other is now reported as Other Operations. Additionally, please note that when we make prospective comments regarding financial performance, including our full year 2021 outlook, we will do so on a basis that includes the potential impact of future share repurchases and anticipated 2021 dividends, and excludes the impact of any business combinations or divestitures that may occur after today, such as our recently announced planned divestiture of the Texas Medicaid business, which we expect to close in the second half of 2021. With that, I will turn the call over to David.

Thanks Alexis. Good morning everyone and thank you for joining us on our call today. Today as we meet, our environment remains highly dynamic, with COVID-19 continuing to impact the world, our industry and our economy. At Cigna, this rapidly changing landscape has only reinforced the tremendous responsibility we have to improve the health, wellbeing and peace of mind of those we serve. This remains the primary focus that drives our 70,000 coworkers each and every day, and it's the reason we work to continue to deliver for our customers, clients, patients, partners and our communities, all while delivering strong financial results for you, our shareholders. During the first quarter, we delivered adjusted revenue of $41 billion and adjusted EPS of $4.73 per share. We also deployed significant capital to our investors through share repurchase and the payment of a meaningful quarterly dividend, reinforcing the strength of our Capitalite framework. Building out our conversation from several weeks ago at our investor day, today I'm going to talk more about how we are continuing to navigate through the current environment to balance and meet the needs of all of our stakeholders, our ability to consistently deliver strong results by executing on our growth framework, and the confidence we have in achieving our increased outlook by delivering differentiated and sustained growth for the long term. Then Brian will share more details about our first quarter results and our 2021 outlook, and after that we'll take your questions. Since we last met at our investor day in March, the macro landscape remains fluid. In the U.S., proposed legislation as well as regulation and executive actions seek to expand, extend, and further support both public and private programs. Globally, social and political tensions remain high as COVID-19 with its multiple variants continues to take a toll on a number of countries, such as India, where cases have again dramatically spiked. All of these forces are shaping healthcare and influencing the political and economic landscape around the world. At Cigna, we are navigating through this environment by continuing to innovate for and support our stakeholders with COVID-19 services, while also executing on our strategy to make healthcare more affordable, predictable, and simple. For U.S. commercial customers, we are ensuring they get the preventative care they need, including mammographies, colonoscopies, cervical cancer screenings, and childhood immunizations, which today are consistent with pre-pandemic levels, reflecting the continued strength of our clinical programs, and proven engagement capabilities. Within Evernorth, for those customers served by Express Scripts Home Delivery, we delivered further improvements in medication adherence for people with diabetes, high cholesterol, and high blood pressure. At the same time, we are also supporting the mental well-being of our customers. We are doing this through our own -in-class capabilities, where, for example, we engage with oncology patients with comorbidities by spending an average of $2,000 on their health care, we can save an average of $20,000 in avoidable costs. And we can innovate and leverage our strategic partnerships, including, for example, with Ginger through Cigna Ventures, which provides industry-leading, on-demand, 24-7 behavioral health coaching, further extending our behavioral health access for the benefit of our customers. We're also leveraging data and actionable intelligence to understand the most common long-term complications of COVID-19 infections, then building predictive models to determine who is at greatest risk of becoming a COVID long-hauler, so we can quickly provide targeted case management and behavioral health services, as well as other resources, to help our customers regain their health. For our clients, we are serving as a trusted partner by supplying additional physical and behavioral health assistance to aid in the recovery for employees who are infected by COVID-19. We're helping employers build their own communities of immunity by assisting them in launching vaccination clinics, and we're leveraging our data and analytics to help employers determine when and how it is safe for employees to return to work. For our provider partners, we're working to guide people to the most effective sites of care and further closing gaps in care with our clinical teams and our virtual capabilities. For our coworkers, we're supporting them in this highly disruptive environment by, for example, providing a $200 incentive for coworkers who choose to become vaccinated for COVID-19 and continuing to offer expanded leave capabilities with our emergency time off program to provide flexibility necessitated by the current conditions. And finally, for our communities, we're taking steps to address social determinants of health. For example, we all know the alarming statistics on the disproportionate impact that COVID-19 has had on communities of color. As part of our SAFE initiative, we brought additional -the-ground resources to target communities by launching COVID-19 awareness campaigns, distributing PP&E kits, dispatching our health improvement mobile resources to help to administer free flu shots, and provide healthy meals as well as other support. Similarly, we're leaning in to fight breast cancer where disparities, for example, amongst Black women remain startling. To help to address this disparity gap, we again went directly into communities, starting in Tennessee, for example, where we collaborated with local partners to offer mobile mammography vans at churches and at other local neighborhood locations. At Cigna, balancing the needs of our stakeholders is deeply rooted in our corporate purpose. We constantly challenge ourselves by asking the basic question, what more could we do? To help us stay focused on delivering each and every day for the benefit of our customers, our clients, patients, and our partners. Against this backdrop, the strength of our foundation propels us forward and guides our growth. As we shared with you at our Investor Day through our three growth platforms, Evernorth, U.S. Medical, and International Markets, we are well positioned to leverage the three trends we see shaping healthcare into the future, specifically pharmacological innovations, the rising demand for coordinated mental and physical health services, and the changing preferences as it relates to access to care models. And through our proven framework, we are able to drive attractive, sustained growth by delivering differentiated value within our portfolio of integrated, coordinated, and point solutions, continuing to work to partner and innovate, and working to expand our addressable markets. As a result, we're off to a strong start in 2021 with strong fundamental execution and the strategic and capital flexibility to further our momentum into the future. During the first quarter, Evernorth continues to build on its differentiated and steady performance it has had delivered throughout the pandemic by evolving the healthcare experience for our customers and clients through continuous innovation, and by building, investing, and strengthening our strategic partnerships. For example, in January, we further expanded our partnership with Prime Therapeutics by leveraging our home delivery and a Credo specialty pharmacy to drive greater value and deliver on our promise to make healthcare more affordable. We're also advancing our strategic capabilities with our MDLive acquisition, which closed last month. This acquisition will expand Evernorth Care's ability to further broaden access, lower cost of care, and strategically position us to grow in the rapidly changing access to care environment. At the same time, Evernorth Pharmacy is also driving affordability improvement. One example is our Patient Assurance Program, which caps the cost of prescriptions for patients with diabetes. During the quarter, the number of patients in this program increased by 64%, and the value of patients delivered from this program is on track to more than double what we achieved last year. Turning to our U.S. medical platform, we see bright spots and growth in our U.S. commercial portfolio. For example, we continue to take Share in the Select segment, which includes employers with 51 to 500 employees. As clients continue to value our integrated, aligned, self-funded medical, pharmacy, behavioral, and stop-loss programs. And more broadly, we're driving value by bringing differentiated offerings to market. Fueled by innovations and advancements, we are accessing from our Evernorth capabilities, particularly in areas of pharmacy services and behavioral health. Through our willingness to strategically partner with innovative companies like Oscar, we're also well positioned to take advantage of market growth opportunities in the small and large employer market, a market we view as currently being underserved. As a result, we expect to see an uptick in growth in our U.S. commercial platform during the residual part of this year. Additionally, one important impact of the pandemic is that businesses have expanded access to support services for their employees by acting as a trusted source of information and providing an extended range of benefits to support whole-person health, as more and more employers recognize the critical link between mental and physical health. In the wake of COVID-19, more employers are also recognizing the connection between healthy workers, higher productivity, and a growing economy. In fact, the National Bureau of Economic Research found that in the U.S., we benefited by $1.5 trillion of value by having employers play a major role in healthcare. This reinforces the critical role our U.S. healthcare business plays as an important partner to employers in providing access to quality, affordable care for the benefit of their employees. Turning to our U.S. government business, we are driving strong -over-year customer growth by continuing to expand our addressable markets. The number of Medicare Advantage customers increased by 11% -over-year, reflecting the ongoing execution of our strategy as well as our sustained strong star performance. And the number of customers in our individual and family plan business grew by 17% -over-year. Driven by our geographic expansion and the introduction of new plans that provide expanded coverage for maintenance drugs to further improve affordability for customers with certain chronic conditions. And in our international markets business, we are focused on actively supporting our coworkers, customers, and partners around the world who continue to be impacted by COVID-19. For example, in India, our foundation is providing financial support through UNICEF to meet the needs on the ground, including additional rapid testing capabilities and expanded access to vaccines. And we're providing matching gifts from the Cigna Foundation to our coworkers who donate to charities in India. Staying true to our mission is not only the right thing to do, it reinforces to our clients, our customers, and our patients our commitment to make a difference in the moments that matter most. Our purpose-driven orientation, together with our strategic flexibility created by our service based model and our capital light framework that generates significant cash flow from operations as well as our track record of strong financial performance where we delivered a 15% adjusted EPS compounded growth rate over the last decade all give us confidence we will continue to sustainably grow in both the short term and the long term in this dynamic environment. And now taking into account the strength of our first quarter results, we expect our full year adjusted EPS to be at least $20.20 in 2021. And we remain confident in our ability to deliver our long term targets of average annual adjusted revenue growth of 68%, average annual adjusted EPS growth of 10% to 13%, and continue to play an attractive dividend while delivering cumulative operating cash flow growth of $50 billion through 2025. Now to briefly summarize, we delivered strong first quarter results by executing our growth framework while harnessing our capital strength to deploy meaningful capital for the benefit of our shareholders, reinvesting in our business, and leveraging our strategic flexibility to continue to innovate and adapt, all of which sets us up for sustained long term success. We remain confident in our ability to continue to grow as we focus our efforts to make health care more affordable, predictable, and simple each and every day. Now with that I'll turn the call over to Brian.

Thanks David. Good morning everyone. Today I'll review key aspects of Cigna's first quarter results, including the ongoing impact of COVID-19 on our business. And I'll discuss our updated outlook for the full year. Key consolidated financial highlights for first quarter 2021 include adjusted revenue of $41 billion, adjusted earnings of $1.7 billion after tax, and adjusted earnings per share of $4.73. Results in the first quarter reflect strong top line growth with contributions across our businesses, and first quarter earnings came in somewhat ahead of our expectations. The favorable first quarter earnings were primarily driven by strong Evernote performance, favorable net investment income, and favorable prior year medical cost development, partially offset by non-recurring operating expenses. Our results reflect our ability to deliver in a dynamic, rapidly evolving environment, including navigating the ongoing impacts of the COVID-19 pandemic. Regarding our segments, I'll first comment on Evernote. First quarter 2021 adjusted revenues grew to $30.6 billion, and adjusted pre-tax earnings grew to $1.2 billion. Evernote's strong results in the quarter were driven by effective execution of supply chain initiatives, continued strong performance in Accredo, our industry-leading specialty pharmacy, and organic growth of our services with deepening partnerships, all while continuing to invest for ongoing growth. Our adjusted pharmacy script volume was $393 million during the quarter, a 9% increase over first quarter 2020. Overall, Evernote continued its positive momentum and delivered another strong quarter of financial results. Turning to U.S. Medical, we entered the year expecting to see the majority of COVID-19 testing and treatment cost pressure in the U.S. medical segment in the first half of 2021, particularly in the first quarter. As we progressed throughout the first quarter, we saw COVID-19 case counts and hospitalizations decline more rapidly than we originally anticipated. Additionally, as COVID-19 cases decelerated, we saw an increase in non-COVID utilization. Importantly, throughout all of this, we continued to see key components of preventive care utilize the pre-pandemic levels for our U.S. commercial customers. Taken as a whole, and excluding prior year medical cost development, our first quarter medical care ratio was in line with our expectations. With that as context, I'll now comment specifically on first quarter financial results for the U.S. medical segment. First quarter adjusted revenues were $10.4 billion, and adjusted pre-tax earnings were $987 million. Our first quarter U.S. medical earnings were slightly ahead of our expectations, primarily driven by favorable net investment income and prior year medical cost development, partially offset by non-recurring operating expenses. Excluding these one-time factors, our U.S. medical earnings were in line with our expectations. Turning to membership, we ended the quarter with $16.7 million total medical customers, an increase of 30,000 customers sequentially. As expected, U.S. commercial customer volume declined sequentially due to disenrollment throughout the first quarter, partially offset by new sales in the select segment, and our U.S. government businesses performed well throughout the annual open enrollment period. Overall, results for Cigna's U.S. medical segment reflect strong fundamentals. In our international markets business, first quarter adjusted revenues were $1.6 billion, and adjusted pre-tax earnings were $262 million, reflecting business growth, favorable net investment income, and foreign currency movements offset by higher claims costs during the period. I would also note that a refinement to the accounting for acquisition costs led to a one-time favorable benefit in the first quarter of 2020 that did not recur in the current period. Corporate and other operations reflect a first quarter adjusted loss of $330 million. These results reflect lower interest expense due to lower levels of outstanding debt, offset by the absence of contributions from the group disability and life business, which was divested on December 31, 2020. Overall, as a result of strong execution and a dynamic environment, we continue to deliver value for all of our stakeholders and strong financial results across our businesses. Now, looking forward to our outlook for full year 2021. As we look to the balance of the year, we expect continued strong execution across our growth platforms, and we expect to make continued meaningful investments in our businesses that are responsive to the force of changing healthcare, positioning us for continued long-term growth. Taken as a whole, we are raising our prior guidance for full year 2021. We now expect consolidated adjusted revenues of at least $166 billion, representing growth of approximately 7% after adjusting for the divestiture of our group disability and life business. We now expect full year 2021 consolidated adjusted income from operations to be at least $7 billion, or at least $20.20 per share. Within our outlook, we continue to expect a full year COVID-19 related headwind of approximately $1.25 per share, primarily within our US medical business. And we continue to project an expense ratio in the range of .5% to 8%. I'll now discuss our 2021 outlook for our segments. For Evernote, we now expect full year 2021 adjusted earnings of at least $5.65 billion. Which represents year over year growth of at least 5%. This outlook reflects ongoing investments in our Evernote portfolio, including investments in care solutions and MD life, as we continue to see significant opportunity to bring new innovative solutions to market. For US medical, we continue to expect full year 2021 adjusted earnings of at least $3.8 billion. This outlook reflects focused execution in our businesses as we expect to drive organic customer growth and deepening of customer relationships. We expect direct COVID-19 related testing and treatment to decline throughout the balance of the year, and also anticipate more normalized non-COVID utilization. And with the strength of the US medical first quarter results, we will further accelerate strategic investments to support future growth, thus leaving our full year earnings outlook for US medical unchanged. Regarding total medical customers, we now expect 2021 growth of at least 350,000 customers. This includes organic growth throughout the remainder of the year in our commercial business, led by the middle market and select segments, partially offset by disenrollment in national accounts. We also expect Medicare Advantage customer growth in our target average annual growth range of 10 to 15%, and we expect continued growth in our individual business. Turning to medical costs, we continue to expect the 2021 medical care ratio to be in the range of 81 to 82%, reflecting the impacts in 2021 of elevated medical costs, including the impact of direct COVID-19 related costs and more normalized non-COVID utilization, and the repeal of the health insurance tax effective for 2021, all while we continue to deliver strong clinical quality and overall affordability for our clients and customers. We also expect continued growth and strong margins in international markets. All in, for full year 2021, we now expect consolidated adjusted income from operations of at least $7 billion, or at least $20.20 per share. Overall, these expected results reflect the differentiated value, strength, and strategic positioning of our businesses as we deliver growth while navigating the impacts associated with COVID-19. Now, moving to our 2021 capital management position and outlook, we expect our businesses to continue to drive exceptional cash flow with strong returns on capital, even as we continue reinvesting to support long-term growth and innovation. For 2021, we continue to expect at least $7.5 billion of cash flow from operations, reflecting the strong capital efficiency of our well-performing businesses. During the quarter, we met our previously stated share repurchase expectations. In -to-date, as of May 6, 2021, we have repurchased 14.4 million shares for $3.2 billion. And we now expect full year 2021 weighted average shares of 346 million to 348 million shares. We ended first quarter 2021 with a -to-capitalization ratio of 39.9%, in line with our long-term target of approximately 40%. We had $2.5 billion of cash available to parent at the end of the quarter, and on April 28, we declared a $1 per share dividend, payable on June 23, to shareholders of record as of June 8. Our balance sheet and cash flow outlook remains strong, benefiting from our highly efficient service-based orientation that drives strategic flexibility, strong margins, and attractive returns on capital. So now to recap. Results in the first quarter reflect strong top-line growth with contributions across our businesses, and first quarter earnings came in somewhat ahead of our expectations. These favorable first quarter earnings were primarily driven by strong Evernote performance, favorable net investment income, and favorable prior year medical cost development, partially offset by non-recurring operating expenses. Our strong results give us confidence in our increased outlook for full year 2021, all while continuing to support our customers, clients, and coworkers. As such, we now expect 2021 full year adjusted EPS of at least $20.20 per share, and have continued confidence in our long-term growth targets. With that, we'll turn it over to the operator for the Q&A portion of the call.

Ladies and gentlemen, at this time if you do have a question, please press star 1 on your touchtone phone. If someone asks your question ahead of you, you can remove yourself from the queue by pressing star 2. Also, if you're using a speakerphone, please pick up your handset before pressing the buttons. Finally, we ask that you please limit yourself to one question to allow sufficient time for questions from those remaining in the queue. One moment please for our first question. Our first question comes from Mr. Robert Jones with Goldman Sachs. Go ahead with your question,

sir. Great. Thanks for taking the question. Maybe just on the PBM, you know, the segment grew pre-tax income 13% year over year, and I think this was the quarter where you were actually lapping some benefits from COVID pull forward last year. So just wanted to see if there's anything you'd call out further within the PBM in the quarter. And then relatedly, if I look at the guidance from this point forward, it does seem to imply for the remaining three quarters, kind of -single-digit growth, income growth within the PBM. So curious if you have line of sight into what might cause a deceleration from the strong performance in the first quarter. Thanks.

Morning, Bob. It's Brian. So thanks for the question. And, yeah, we're really pleased with the strong start to the year in Evernor, which, as I mentioned in my comments, gives us the confidence to increase the full year guidance to at least $5.65 billion of operating income. Quarter to quarter, there will be some level of variability in this segment, so I would encourage you not to overreact to the singular quarter that we had here, but certainly pleased with 13% quarter over quarter earnings growth. I would remind you that our prime therapeutics partnership launched April 1st of 2020, so the base period last year in the first quarter did not have contributions from prime therapeutics. So that was a bit of a benefit to this quarter that will not recur to the same degree for the balance of the year. So to your point on the operating income growth appearing to slow to some degree later in the year, that's one contribution that you should keep in mind. Additionally, we continue to invest aggressively in Evernor to expand and diversify the suite of solutions in that portfolio. So as you think about care solutions, benefits management, insights, we will make continued organic and on a targeted basis inorganic investments to continue to expand that portfolio, which will increase SG&A to some degree, temper the income growth for the balance of the year. David, anything you want to add to that? Just highlighting the

fact that in support of that, for example, our Evernor's benefits business performed very strongly in the first quarter. So on a -over-year basis, that was a partial contributor to the -over-year increase as Brian articulated. And we remain committed to continue to invest in the businesses all while meeting now our increased earnings outlook for the full year.

Great,

thanks.

Thank you, Mr. Jones. Our next question comes from Mr. Ralph Jacoby with Citi. Your line is open. You may ask your question.

Thanks. Good morning. The SG&A on the US medical side was higher and I think you mentioned nonrecurring operating expenses. So just hoping you give a little bit more details on what that exactly was and if you're willing to quantify that amount.

Morning, Ralph. It's Brian. So maybe let me unpack the US medical nonrecurring items a little bit. I know this might speak to the core of your question a little bit. As I mentioned in my comments, overall our US medical earnings in the quarter were above our expectations. When you removed the effect of the three nonrecurring items, we were in line with our expectations. So the three nonrecurring items that I cited, we had some favorability in the quarter in net investment income. We had some favorability in the quarter in prior year medical cost development and that was offset by nonrecurring operating expenses. And so to the core of your question, the nonrecurring operating expenses you can think of as litigation oriented matters associated with operations from several years ago. So these are not related to current time periods. These are unrelated to Anthem. These are matters from several years ago, but they're related to operations. And as a result of that, we chose to book them through SG&A as opposed to considering them as a special item below the line or anything like that. They were appropriate in our eyes to book through SG&A above the line. And order of magnitude, you can think of that as approximately offsetting the favorable benefit that we had from net investment income in the quarter within U.S. medical. But those are truly nonrecurring items since they're related to periods from several years ago and those matters should now be closed.

That's awesome. Thank you. Thank you, Mr. Jacoby. Our next question comes from Mr. Justin Lake with Wolf Research. You may ask your question.

Thanks. Good morning. I wanted to squeeze in a couple of quick questions. First, in terms of medical cost expectations through the year, you gave us an update on COVID, but wanted to get an idea of what you're thinking into the back half of the year in terms of utilization, pickup, post the vaccine, what you've built in versus kind of typical trend. And then you mentioned you'd invested, planned to sell that Texas Medicaid business. Just wanted to see if there's any background there in terms of which road you think kind of the best at and any kind of updated thoughts on your Medicaid strategy going forward to be helpful.

Thanks. Hey, Justin. Good morning. It's David. Let me just frame the medical cost for a moment and then ask Brian to talk a little bit more about our framework and our expectations for the year. And then I'll come back and address the Medicaid divestiture and our Medicaid direction more broadly. First, from a medical cost standpoint, big picture. We're pleased with the start to the year. Big picture, broadly speaking, we're pleased with the start to the year. And I just want to underscore a couple of components. One, our organization works tirelessly to try to drive elevated utilization of certain services like preventative care services. And importantly, we saw in the first quarter the use of preventative care services like mammographies, colonoscopies, childhood immunizations, cervical cancer screenings to be at an approximate level of pre-pandemic levels. That's a tremendous result offsetting what might have been a dampening utilization. The national data we see more broadly is that utilization of those preventative care services is at a more dampened rate, but ours is at an elevated or more consistent rate from that standpoint, which is quite important. Secondly, I would just remind you that, and I'll tie this back in our Medicaid comment a little later, is that we have a de minimis amount of Medicaid within our portfolio and our national data suggests through our services business, through our services business, that in the first quarter Medicaid medical costs were a bit more dampened year over year in the first quarter of 2021. That's not an effect on our portfolio, but we can see that in the services that we're providing. I'll ask Brian to give you a little bit more color forward looking on the year, then I'll come back and address Medicaid.

Yep, so good morning, Justin. So just a few other comments on the quarter and the balance of the year. Overall, as I mentioned in my comments, the U.S. Medical MCR was in line with our expectations for the first quarter. When you exclude the benefit of PYD or prior year development, when you include the benefit of prior year development, we were actually a little bit favorable in the first quarter. And that was at an elevated level as we expected when we stepped into the year. For the balance of the year, we expect a deceleration in COVID-19 testing and treatment costs. We expect an uptick in non-COVID related utilization in quarters two through four. And we expect to see a deceleration in the second quarter with those factors roughly offsetting one another. And so when we constructed our full year out of an 81 to 82% medical care ratio, we stress tested a variety of scenarios associated with those two levers and are quite confident in our ability to achieve the full year 81 to 82% medical care ratio for U.S. Medical. David, maybe on the Texas Medicaid and our broader Medicaid strategy, over to you.

Sure, Justin. As you noted, we chose to divest of that single site Medicaid operation we had. So number one, it was we have one of one. So it was one off within our portfolio. It has a de minimis impact on our P&L at the enterprise level. So putting that aside, we determined it was best for that business to be served by an expert or a specialist and we're pleased to effectuate and seek to close a successful transition to Molino. We think that's beneficial to the customers being served and our coworkers in that business. Looking forward, we continue to see Medicaid and government services first of all as an attractive growth opportunity within our EverNorth service portfolio, whether it's EverNorth Pharmacy, EverNorth Care, EverNorth Benefits, EverNorth Intelligence. The opportunity to bring expanded services largely through health plans today in support of Medicaid will be a growing organic part of our portfolio. Over time, we see opportunities that will manifest themselves state by state on state specific service relationships again through EverNorth. And then finally, as you recall from our investor day conversation within our M&A priority, we continue to have an expansion of our U.S. government programs as an M&A priority. So we'll be opportunistic from that standpoint if we see the ability to further strengthen any of our capabilities looking forward. But that divestiture was again, it was a one-off, de minimis impact and we deemed it was best in the hands of a specialist. Thanks, Justin.

Thank you. Mr. Lake, our next question comes from Mr. George Hill with Deutsche Bank. You may ask your question.

Yeah, good morning, guys, and thanks for taking the question. I guess, David, I would ask a little bit more color about the MDLive acquisition and how you guys are thinking about care delivery partnerships. And I'd love a little bit of commentary maybe on how the digital formulary is progressing and if you could maybe talk about if that's got a meaningful revenue contribution yet to the EverNorth segment.

So thanks for the question, George. So specific to MDLive, first important to reference the fact that we had a multi-year relationship with MDLive, both partnering to consume the services, but also through our very successful multi-year Cigna Ventures organization. So we start from a learned shared experience and even deeper collaboration during the COVID environment. Specific to the asset and the direction, as we discussed at our investor day, we see rapid expansion of what we call alternative side of care to be one of the three major trends as we look forward over the next five to 10 years. This is an important part of those building blocks and it's a very important part of our EverNorth care portfolio of capabilities. We see it as much greater than telemed or even basic virtual care triaging. We see the ability to obviously expand virtual care, primary care, behavioral care. We see the ability to expand that further in terms of longitudinal chronic care programs, polychronic and ultimately complex care programs and capabilities. So it provides us an accelerant to our strategic direction with a known partner that will now be part of the overall Cigna portfolio. And we're excited because NetNet, it drives improved service, improved access, improved affordability with strong clinical outcomes for the benefit of our consumers. So truly an aggregate win-win in the portfolio. Specific to the digital formulary, that innovation continues to be somewhat unique in the marketplace. Our clients really appreciate the approach relative to the digital formulary, helping to essentially curate and apply externally validated expertise to the vast array of digital alternatives that exist in the ecosystem to help to provide employers more informed decisions for those that may have the greatest outcome and impact for the benefit of the customers. So I view that as a part of our consultative approach in terms of providing support and a part of our approach to, in this case, partner and curate additional services on a go-forward basis. As a whole, we see, again, our EverNorth care capabilities as an exciting part of the broader EverNorth growth capabilities, and we see the ability to do that in a complementary nature with our proven value-based care relationships within our Cigna portfolio as well. Hope that helps,

George. Thank you, Mr. Hill. Thank you, Mr. Hill. Our next question comes from Mr. A.J. Rice. Your line is open, sir, with Credit Suisse. You may ask your question.

Thanks. Hi, everybody. I'm going to just ask about the selling season both for Medical and for EverNorth on the PBM side. I know last year there was some discussion about potentially people being delayed, different people had different views as to how much of that activity actually happened. I wondered what you've seen in terms of RFP activity on both sides of the business, anything to discuss in terms of, you know, new and innovative ways that Cigna is going to market in those two sides of your business and any discussion about early wins, losses?

A.J., good morning. It's David. So relative to the selling season, looking to 2022, your question goes at the commercial side as well as the services side of the business. First, on the commercial side of the portfolio, at this stage of the year, we're typically looking at the national accounts environment. And remind you that we define national accounts for our US commercial portfolio a little bit more narrowly than some in the market. So it's commercial employers, 5,000 or more employees who are multistate in nature. As we look to 2022, right now we see an environment where the RFP volume, so the opportunity to pursue new business, is up somewhat. Think order of magnitude 10%. And we see the portion of our book of business that's out to bid is being up marginally less than that 10% number. So that's a little bit of framing. We have some early traction, some early wins that exist in our portfolio. And as we sit here at this stage of the environment, we're optimistic that we'll have a very good commercial outlook and aggregate for our portfolio as we look to 2022. I'll bridge with a trend comment and then I'll come to the Evernorth portfolio. Clearly, affordability remains a top decision. We have a very high valuation criteria for commercial employers. There's no doubt about that. We spent ample time on that at our investor day and it remains a top strategic imperative. Further beyond that is the flexibility necessary and then the innovation required to truly integrate or coordinate mental and physical health programs and then expand and coordinate access to care in a less fragmented way through alternative side of care framework, etc. So we see the trends being well lined up to our direction. As relates to within Evernorth and specific to your question within pharmacy services, as you recall, we have now multiple years of very attractive growth under our belt as a combined organization. And we're pleased with that. As we look to 2022, we have an environment where to date our employer renewal process is manifesting itself quite strongly. And our health plan renewal process is manifesting itself rather strongly beyond the two known losses that we previously discussed relative to the health plan business. Taken as a whole, we'd expect the retention in that business as we see it right now to be a bit less than our recent couple of years, which have been historic highs in the upper 90s. We'll expect it to be more in the mid 90s as a consistent rate. And then taken as a whole, we will expect to see both revenue and earnings growth in our Evernorth portfolio in 2022. So both pointing in a positive direction would be the summary I would leave you with.

OK, great. Thanks.

Thank you, Mr. Rice. Our next question comes from Mr. Kevin Fishback with Bank of America. You may ask your question.

OK, great. Thanks. The way that you were framing the drop off in COVID utilization and then I guess the earlier return in volumes to me implied that the COVID impact might actually end up being less than what you were forecasting. But you obviously reaffirmed that number. So just any thoughts about the puts and takes of COVID dropping faster than you thought? And then do you still feel like about half of that coming back next year is the right way to think about that?

Thanks. Morning, Kevin. It's Brian. I appreciate the framing of it. Broadly in the quarter, as I said earlier, the MCR for U.S. medical was in line with our expectations when you exclude the favorable benefit from prior year development. Now, the components within were a little bit different than we anticipated. So to your point, the COVID-19 testing and treatment burden on our book was a little bit lower than we anticipated for the quarter. However, non-COVID utilization was a little bit higher than we anticipated coming into the quarter. So the net effect of those two factors led to the U.S. medical MCR being back in line with where we expected it to be. As we trend out the balance of the year, we continue to expect that phenomenon to proceed, meaning deceleration in COVID-19 testing and treatment costs and a little bit of an uptick in non-COVID related utilization. So to your point, we expect about 50% of the EPS headwind associated with COVID-19, the $1.25, to continue to show up in the U.S. medical MCR. And bridging over into 2022, we continue to anticipate about half of that $1.25 or a little bit over half of that to return in the form of earnings in our 2022 enterprise portfolio. And as such, we would expect that our long-term annual growth rate in EPS of 10% to 13%, we would expect to achieve a result that's at or above the high end of that range relative to our updated guidance of at least $20.20 per share.

A couple of

thanks. Thank you, Mr. Fishbeck. Our next question comes from Ms. Lisa Gill with JP Morgan. You may ask your question.

Thanks very much for taking my question. I just wanted to go back, David, and ask a question around the comments that you made around MD Live. Specifically, you talked about expanding primary care and longitudinal care. You talked earlier about your relationship with Ginger around mental health. So my question here is really twofold. First, where do you see the opportunities with MD Live around lowering overall medical costs for Cigna? Second, do you believe that you need to buy or continue to build out something around behavioral health? And then, thirdly, can you just give us an idea of how many Cigna Lives actually use MD Live today?

Lisa, thanks. I appreciate the ongoing interest in the space for sure. So, number one, bigger picture framing. I appreciate that you brought MD Live, Ginger, together, for example. We do not believe that this is a -and-done type activity. So we don't believe that a corporation secures itself a virtual care asset and then they're squared for the alternative delivery space. This is a fluid environment. It's a dynamic environment. And it's an environment that has massive promise relative to bringing expanded access, core services, and more. It's a combination of services and improved overall value coming back to the affordability. Our organic capabilities are strong. The MD Live asset advances that massively. But as Brian noted in his prior comments as well, we continue to invest in the space. So I want you to view that we view it as a dynamic and fluid space and we very much like our positioning. Two is, just like in the, we'll call it the traditional care delivery space, the coordination of physical and mental health is mission critical. Just because it's in a virtual care environment doesn't mean that the coordination or the leverage opportunity there is not critical. And in fact, the virtual capabilities allow us to take fragmentation out of the system more aggressively and more comprehensively. To your affordability comment, unequivocally we see an ability to further improve affordability through alternative site of care and through our virtual capabilities. You may recall from Investor Day we identified alternative site of care or site of care leverage as a meaningful opportunity to further deflect or improve overall affordability. And an example may be, we see already in our virtual care delivery, less use of unnecessary or redundant diagnostic services. That's a tangible illustration of an improvement in affordability. Conversely, we see opportunities to even further close gaps in care or increase user experience. And we see that through the utilization of the right services like maintenance medications, through the dynamic, more intimate, ongoing interaction with customers or patients from that standpoint. So my points are threefold. One, continuation of investment here and innovation off of a very strong base. Two, a continued need to use the capabilities to close fragmentation within the system or get more complimentary leverage, most notably between the medical health and the health and safety capabilities. And three, unequivocally a contributor to further improve affordability.

Thank you.

Thank you, Ms. Gill. Our next question comes from Mr. Josh Raskin with Nefron Research. Hi,

thanks. Good morning here with Eric Purchter as well. Can you speak to the progress in both the individual exchanges? I think I heard a 17% number as well as the small group that is working on the innovation around medical cost and sort of utilization of new products, et cetera, to better understand sort of profit trajectories here this year.

Hey, Josh. Good morning. It's David. Let me just start and frame the growth trajectory and then ask Brian to provide a little bit of additional color relative to our insights on the performance. First, we're very pleased. We're very pleased with the sustained performance starting with the individual exchanges. Just to have you recall, we entered the exchanges in the first year and we've sustained engagement in the exchanges since its inception. We've innovated within the exchanges. We've delivered a proven model and now we're in an expansion mode relative to additional geographies in large part with our collaborative accountable care and aligned value-based relationships from the healthcare delivery system. And we're pleased with the results, both the base results and the overall performance as well as thus far our early look at the additional enrollment we're seeing because the expanded SEP and I'll ask Brian to give you a little color relative to that dimension. As relates to the small employer marketplace, as you know, we, Cigna, historically have not played in the small employer marketplace. We've focused above 51 lives or above 100 lives depending on the regulation more broadly. We have continued to view it as an underserved market, a market that is more traditional or rigidly designed programs, less innovation and less flexibility and less leverage of more modern specialty and clinical services. And our determination was it was best to pursue that market in partnership, leveraging our partnership DNA and we've entered that market successfully with our partnership with Oscar. We're really early in that journey, some positive indicators for sure, we're early in the journey. Our early indicators are positive though that has us accelerating our geographies and in collaboration with Oscar and again back to in partnership with our healthier delivery partners. So Brian, maybe just a little color in terms of what we view the SEP process looking like and the economics within the individual exchange. Sure,

Marty, Josh, our individual membership year to date is a little bit above our expectations for a couple of different reasons. One is I'm sure you know we stepped into 80 new counties in the last year and the new enrollment period there was a little bit above our expectations. Additionally, the expanded special enrollment period window that President Biden introduced has generated some new lives in our portfolio as of the end of the first quarter. We have no reason to believe at this juncture that those customers perform meaningfully differently than the balance of our individual exchange portfolio to your point on when will we know for sure. It will take several months as we understand the risk adjuster profile and the persistency of the individual exchange membership only represents about 5%, 6% of our total U.S. medical portfolio so it won't be a significant needle mover relative to the MCR full year outlook for U.S. medical.

Thank you.

Thank you, Mr. Raskin. Our next question comes from Mr. Scott Fedell with Stevens. You may ask your question.

Hi, I'm Fatsin. Good morning, everyone. A question just first if it would be helpful if you maybe could talk about the $1 billion race revenue guide and how you would sort of break that down between each of the three segments and then also interested just in sort of what you're seeing in aggregate right now around the debate around inflation and not just think about medical inflation but obviously Cigna has a lot of insights into just general inflation dynamics across all of your businesses. So interested in terms of what you're seeing in the first quarter as it relates to whether you're actually seeing inflation rates and the impact that that's going to have on inflation rising and how you're thinking about the outlook for that over the course of the year.

I'm going to ask Brian to give you a little color on our really strong sustained revenue performance and then I'll come back and see if you can address your inflation question.

Good morning, Scott. So really pleased with the Q1 performance on revenue as well as the full year increase in our guidance of at least $166 billion. You should think of the majority of that increase We're also seeing strength within U.S. medical. So I would think of most of it from Evernorth and a bit of an uptick in U.S. medical as well. David, back to you on the inflation question. Sure. Scott,

on the inflation question, I'm going to come at it two ways. First through the core visibility of our business and then more broadly for those we serve. Thus far within our business, we do not see a large trajectory I would say there is always some. Make no doubt about it. There is always some. But through ongoing innovation, ongoing productivity, ongoing value-based collaboration, broadly speaking I would not call a large sea change from that standpoint. Beyond that in the broader economy, whether we look at it through a U.S. lens or pockets of oil or oil, we do not see it. One is the relative triggered across a threshold to suggest to any one industry, save for some unique outliers, any kind of orange going to red threshold levels of inflation. But the robustness of the economy and some of the underlying cost drivers in some subsectors are clearly beginning to elevate, and I think have a lot of industry leaders watching to ensure that any movement in curves, any rising actions like CPG companies that are being intensely discussed, cost pressures in some subsectors of the technology ecosystem where the chip industry is out of pattern relative to supply and demand from that standpoint. But broadly speaking, I would say again, nothing affecting our space over the immediate-term horizon from an inflationary standpoint.

Okay. All right. Thanks.

Thank you, Mr. Friedel. Our next question comes from Mr. Matthew Borsch with BMO Capital Markets. You may ask your question.

Thank you. Let me ask a question about Medicare Advantage and the outlook, how you think it's going to work with rates. I know that I'm asking about 2023, and I know that's a light year away, but my question Medicare Advantage benefited from the lower expenses in 2020. I'm wondering how you think that's going to roll through the rate calculation because right now CMS has 2020 down 8% per capita and then increasing about 11% in this year and the next year. And so I guess my question is, do you think that kind of trajectory is likely for medical costs? And then if you can comment on it, how you think that might work into the 2023 rate?

Matthew, a pretty complex rubik's cube you put on the table. Thoughtful, but nonetheless complex. I think as you – as I take your question and process your question, if you look at the 2020 to 2021 environment, clearly the posture of CMS recognized the COVID dislocation, recognized that dislocation, for example, implication on risk adjusters, sought to, in their own methodology, seek to provide some offset to that relative to their rate setting environment as well as their guidance relative to delivery system reimbursement and set themselves up for what I would say is a pretty fluid and complex environment over the ensuing couple of years ahead. So I would expect the next couple of year cycle to be a little nontraditional from that standpoint given the need to adjust the various moving parts that result in a net rate setting environment. History would tell us that the result of all of the above, plus or minus a point or two, largely gets the program to a balanced, sustainable outcome. And looking forward, I would expect that because the Medicare Advantage program continues to deliver outstanding value, as you know, for seniors, hence the tremendous support from a senior standpoint as well as overall clinical quality and affordability of which through the bonus programs and the reimbursement programs the federal government's budget actually benefits from. So I would expect it to be able to be balanced through that, but a little bit more lumpy than it has been in the past. And I think this year's risk adjuster true-ups will be really mission critical in terms of how CMS sees the industry recapturing a little bit more of the information that they deem necessary to get the risk adjusters, and then they'll factor that into the forward-looking 2023 read environment. Stay tuned for more.

Okay, good. Thank you.

Thank you, Mr. Borz. Our next question comes from Ms. Ricky Goldwasser with Morgan Stanley. You may ask your question.

Yeah, hi. Good morning. Thank you for taking my question. So one follow-up, David. You talked about sort of the return of some of the diagnostic procedures that now are in line with before pandemic. Are you clearly, acuity is a big uncertainty for the rest of the year, but now that you are starting to have this data, as individuals are starting to come back for preventive care testing, are you seeing any changes in acuity? That's one. And then my second question goes back to M&A and investments, clearly a very big focus and part of your growth strategy. So what metric do you use when you evaluate a buy versus a partner or a billed decision?

Ricky, good morning. It's David. Let me take both of your questions. On your first question, to be very clear, we have seen consistent, strong utilization of preventative care services and notably what I called out is, for example, in the first quarter of 2021, broadly speaking, preventative care services inclusive of mammographies, colonoscopies, childhood immunizations, cervical cancer screening, plus or minus in the commercial portfolio business approximate pre-pandemic levels. We think that's a very good thing. Let me underscore. It's a very good thing and something that our team has worked tirelessly to try to effectuate elevating those levels. We see that performance against a national data set that suggests the utilization of preventative care services are down versus pre-pandemic levels, 10 to 15%, but for our book of business they are not. As a predictor then to the future, we see that as a mitigant for an elevation of acuity. All other things remain equal because you're consistently identifying an earlier stage through the preventative diagnostics or the preventative services. Equally as important as I noted in my prepared remarks are, for example, within our ever North portfolio and within our ever North pharmacy portfolio, for those customers being served by our mail order, we've actually seen yet even further elevation of medication adherence. That's really important for the chronic population to avoid spikes in acuity moving forward, whether it's for diabetic, COPD, asthmatic, or other patients from that standpoint. Broadly speaking, we're working tirelessly to get the right clinical quality and services to be consumed and supported with the clinical resources we have to avert spikes in acuity going forward. Therefore, we don't expect a large spike in acuity on a look forward basis given the strong preventative or medication compliance. As it relates to your M&A question, there's not a simple way to answer your question. Importantly though to frame, we look at all either growth or expansion of capability opportunities through buy, build, ally frameworks. We relentlessly go through a buy, build, ally framework. For example, today within our ever North benefit portfolio, we're organically building out additional post-acute care capabilities after evaluating, buying, further partnering, or insourcing those capabilities. We typically will look at that through a right to win, a strategic positioning, and an economic framework. You'll look at it through a variety of frameworks. It's not a simple economic hurdle rate. Your question didn't infer that it was a single measure, but it's not a single economic hurdle rate. It's through a right to win size and trajectory of the market, the resources with which to pursue, whether it's organic build, collaboration through a partnership, or from an acquisitive standpoint. Obviously, certain economic hurdle rates come into play, which we don't discuss publicly. Those are proprietary, but you would imagine we're quite disciplined in terms of our return capital thresholds. Ricky, hope that helps.

Thank you. Thank you, Ms. Goldwasser. Our next question comes from Mr. Stephen Balliquette with BarCase. Your line is open. You may ask your question.

Thanks. Good morning, everyone. So there was a question earlier on inflation. I actually have a question on deflation. I just want to check the box and get your quick thoughts on generic pricing as there's been some mixed signals on the level of generic deflation in the first quarter. I guess I was curious, was there any evidence of accelerated deflation that may have played a role in better cost of goods sold in your mail order operations within EverNorth? Also, you mentioned the effective supply chain initiatives again this quarter. I'm just curious what that means for 21 in particular. Is that just code for better drug purchasing and procurement this year, or are there other factors within the quote unquote supply chain initiatives driving better results? Thanks.

Good morning. David. So two-point question. First, there's no doubt there are some pockets of generic deflation within the pricing environment and within the cost environment. Importantly, they're in line with our expectations. So it's not a deviant or driver of a deviation for us in any way, shape or form in terms of our broad portfolio. But unequivocally, there are some pockets of deflation there in line with our expectations. As it relates to the supply chain activity, I would ask you just to continue to think about supply chain initiatives as being an inherent strength within the overall portfolio through a variety of lenses, whether it's collaboration on the medical side of the equation, the traditional supply chain activity, the value-based supply chain activity, et cetera. And we have a continuous drive to improve value, albeit to partner as we go through the process. And as we get into some more of the complex dimensions of the higher-cost drugs and medications, we think there's further opportunity through the supply chain activity around value-based care relationships, aligned incentive relationships more specifically with the manufacturers and with ourselves on a go-forward basis. So I wouldn't call out any unique driver. More importantly, it's a continuous improvement part of our portfolio, and it's an underlying strength of our portfolio. And lastly, our sustained growth supports that in a very positive way. Got it.

Okay. Thanks.

Thank you, Mr. Velikot. Our last question comes from Mr. David Winley with Jeffreys. You may ask your question.

Hi. Good morning. Thanks for squeezing me in. I wanted to come back to the telemedicine topic and, David, thinking about your capital light strategy relative to providers and network, I'm wondering if EverNorth and Cigna has an opportunity to leverage MDLive into your collaborative care partnerships or otherwise into partner networks as opposed to own networks in your case? And then alternatively, do you have an opportunity to use MDLive to feed volume or refer volume, catch volume, so to speak, in other parts of EverNorth, especially pharmacy, mail order delivery, things like that by owning and controlling telemedicine through MDLive?

Good morning. Appreciate the question. So twofold. To the first part of your question, the simple answer is yes. So to be really clear, again, we see the opportunity obviously from a stand-alone, if you will, fulfillment and delivery of the service, but also an opportunity in collaboration, in alignment as a panel extender for high-performing collaborative and accountable care relationships. And those conversations are dynamic and underway. To the second part of your question, very thoughtful framework and appreciate it, if we come back and think about first and foremost our ability to further improve affordability, you may recall at our investor day we talked about four major ways in which we further improve affordability off of our strong overall cost environment today. One is to further increase the percentage of utilization that takes place in the highest-performing clinical settings, be they physicians or facilities. Second is to work to reduce the cost of drugs further. Third is to effectively leverage alternative sites of care. For example, the difference between a knee replacement that is inpatient versus outpatient is about a third less in cost, and we see a massive shift. That's a physical side of care. It's similar in virtual side of care. And then fourth, the ability to further coordinate the fragmented system, specifically in the areas of medical and behavioral. So back to your question, our evolution of our telemedicine and virtual care capability present opportunities to contribute to a variety of these areas, to help to support individual customers or patients accessing higher cost healthcare specialists or delivery system partners, helping to drive further leverage relative to the pharmaceutical equation in terms of medication compliance or alternative lower cost medications, and the ability to merge or coordinate services, be they behavioral and pharmacy, behavioral and medical, by being in that quarterback position with a customer or patient from that standpoint. So we see it as being complementary to a variety of those initiatives, and we see it being both complementary to your first question, proprietary driving on our own, and in collaboration as a panel extended for high performing healthcare professional partners. Thanks for the question.

Yeah, thank you.

Thank you, Mr. Winley. I will now turn the call back over to David Codani for closing remarks.

First, thanks for our time today. We really appreciate spending time to discuss our signal results and our outlook. I just want to wrap up our call with a few headlines. First and foremost, we delivered strong financial performance during the quarter as we continue to navigate through what is undoubtedly a dynamic environment, and we work to meet and balance the needs of all of our stakeholders as we act as champions for healthcare that is affordable, predictable, and simple. In addition, our strong foundation driven by our growth framework and track record of success gives us confidence in our ability to achieve our increased EPS outlook for 2021 of $20.20, as well as positions as well for our ongoing long-term average annual revenue growth rate of 68% and our 10% to 13% average annual adjusted EPS growth rate, all while continuing to pay an attractive dividend. With that, again, we thank you for joining our call, and we look forward to our future conversations.

Ladies and gentlemen, this concludes Cigna's first quarter 2021 results review. Cigna Investor Relations will be available to respond to additional questions shortly. A recording of this conference will be available for 10 business days following this call. You may access the recorded conference by dialing -551-8152 or -369-3810. There is no passcode required for this replay. Thank you for your participating. We will now disconnect.